Status:
COMPLETED
Bupropion For Reducing High-Risk Behaviors in Depressed Men Who Have Sex With Men (MSM)
Lead Sponsor:
NYU Langone Health
Collaborating Sponsors:
National Institute on Drug Abuse (NIDA)
GlaxoSmithKline
Conditions:
HIV Infections
Depression
Eligibility:
MALE
18+ years
Phase:
PHASE1
Brief Summary
The primary purpose of this study was to test the whether high-risk, HIV-seronegative persons with mild-to-moderate depression would be more likely to adopt protective behavior change when provided wi...
Detailed Description
Depression in men is often masked by high-risk behaviors such as alcohol and drug abuse. Common symptoms among depressed men include feelings of hopelessness and helplessness, irritability, and anger....
Eligibility Criteria
Inclusion
- Available for at least 9 months, or the duration of the study
- Willing to complete HIV testing and counseling
- History of HIV testing and counseling
- At high risk of HIV infection, indicated by more than one male sexual partner in the 3 months prior to study entry
- Meets criteria for either (a) major depression or dysthymia within a mild-to-moderate level according to standard criteria DSM-IV, or (b) minor depression as defined by one or more of the following symptoms at any time and for any duration during the past 12 months: significant weight loss or gain, or significant decrease or increase in appetite; poor sleep pattern; noticeable irritability or slowness; fatigue or lack of energy; inappropriate feelings of worthlessness or guilt; inability to concentrate; indecisiveness; and recurrent thoughts of death or suicide.
Exclusion
- HIV infected
- Sexual intercourse in the 3 months prior to study entry with only one partner, and in a monogamous relationship
- Currently enrolled in another study involving repeated HIV testing and counseling
- Receiving treatment for depression with antidepressant medication for any length of time within the year prior to study entry
- Currently in psychotherapy, psychoanalysis, or any other form of talk therapy for any reason
- Severe depression or at suicidal risk
- No evidence or prior history of depression
- Homicidal or other similar problem that, in the opinion of the investigator, may endanger study staff and participants
- Currently taking monoamine oxidase inhibitors (MAOIs). Participants may be allowed to enroll 14 days after discontinuing use of a MAOI.
- History of seizures
- History or current symptoms of bipolar disorder
Key Trial Info
Start Date :
September 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2004
Estimated Enrollment :
41 Patients enrolled
Trial Details
Trial ID
NCT00285584
Start Date
September 1 2002
End Date
September 1 2004
Last Update
December 12 2017
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Bellevue Hospital Center
New York, New York, United States, 10016-3240
2
New York University School of Medicine
New York, New York, United States, 10016-3240